Endoplasmic reticulum (ER) News and Research

RSS

Physiological differences between men and women impact colorectal cancer progression

Physiological differences between men and women may contribute to differential tumor development and progression in colon cancer patients, a study led by researchers at the University of Southern California (USC) suggests.

5 Jun 2007

Benefits of Herceptin are lasting

An updated analysis of two large randomized clinical trials has found that breast cancer patients who received the monoclonal antibody trastuzumab (Herceptin) along with chemotherapy are living longer and with less risk of recurrent disease, compared to patients treated with chemotherapy alone.

5 Jun 2007

New discoveries on genes implicated in Fanconi anaemia

An international research consortium, which included the participation of the Mutagnesi Group from the UAB, has made outstanding progress in the study of Fanconi anaemia.

3 Jun 2007

Obese people more likely to have persistent or severe persistent asthma

A new study presented at the American Thoracic Society 2007 International Conference finds that obese people are significantly more likely to have persistent or severe persistent asthma than their thinner counterparts.

24 May 2007

Promoter hypermethylation is common in breast cancer

Cancer epidemiologists at the University at Buffalo have identified specific genes that are most likely to become cancer promoters when exposed to a process called DNA promoter hypermethylation.

17 May 2007

Specific genes identified that are most likely to become cancer promoters when exposed to DNA promoter hypermethylation

Hypermethylation is a process that causes genes that promote normal cell growth to produce proteins that cause malignant behavior, or unregulated cell growth. Until now, data has been very limited regarding the mechanism and causes of hypermethylation, especially for hypermethylation in breast cancer.

15 May 2007

Influence of the cellular microenvironment on breast cancer

This month The American Journal of Pathology highlights the influence of the cellular microenvironment on breast cancer by promoting three articles from the current issue.

27 Apr 2007

Succimer therapy improves balance and movement in lead-exposed children

University of Cincinnati (UC) environmental health researchers say a therapy commonly used to remove dangerously high levels of lead from the body may also improve muscle functions associated with postural balance and movement in lead-exposed children.

25 Apr 2007

Decrease in breast cancer incidence linked to drop in HRT

A special report in the April 19, 2007 edition of The New England Journal of Medicine concludes that the sharp decline in breast-cancer incidence in 2003, followed by a relative stabilization at a lower rater in 2004, is most likely related to the first report of the Women's Health Initiative (WHI).

19 Apr 2007

Breast cancer incidence continues to trend low in 2004

An extended analysis of cancer rates reinforces a strong association between use of hormone replacement therapy (HRT) and increased breast cancer incidence, according to research led by scientists at The University of Texas M. D. Anderson Cancer Center and published in the New England Journal of Medicine.

19 Apr 2007

Drop in HRT use linked to decrease in breast cancer rates

According to the latest report the drop in the use of hormone replacement therapy (HRT) in mid-2002, following the results of the Women's Health Initiative study (WHI), is linked with a steep decline in new breast cancer diagnoses.

19 Apr 2007

New findings on salicylates may lead to more effective aspirin-like drugs

Salicylates, including aspirin, are used to treat a range of inflammatory conditions and can be used to prevent diseases such as cancer, but the way aspirin works is not yet fully understood.

7 Apr 2007

Although breast cancer mortality has declined as a whole, declines are greatest for women under 70

A new study shows that recent declines in breast cancer mortality rates have been most significant among women with estrogen receptor (ER)-positive tumors and women younger than 70.

4 Apr 2007

Chemotherapy and tamoxifen combination improves survival for early-stage breast cancer patients

Patients with early-stage breast cancer who are treated with both chemotherapy and tamoxifen have a higher survival rate than patients who receive only tamoxifen.

3 Apr 2007

Triple negative breast cancers more common among women who are African American and Hispanic, under 40 years old

So-called "triple negative" breast cancers, tumors that do not contain any of three significant tumor markers, are aggressive, deadly cancers that affect young, poor minority women, according to a new study.

2 Apr 2007

New system to speed critical care to acute heart attack patients

Mayo Clinic has designed a new system to speed critical care to acute heart attack patients that dramatically reduces the time that elapses before patients undergo a life-saving procedure -- by as much as 45 percent in some cases.

2 Apr 2007

Penwest confirms action on Oxymorphone patent application

Penwest Pharmaceuticals has confirmed that the U.S. Patent and Trademark Office (PTO) has posted on its website an indication that a final rejection of Penwest's patent application claiming the sustained release formulations of Oxymorphone will be mailed.

15 Mar 2007

New method for identifying viruses and bacteria that cause common infections in children

Infectious disease specialists at UT Southwestern Medical Center have found a new method for identifying suspect viruses and bacteria that cause some of the most common acute infections in children.

13 Mar 2007

Tamoxifen offers long-term benefits for breast cancer prevention among women at high risk

The trials found that the breast cancer risk reduction persists long after women stop taking tamoxifen.

20 Feb 2007

Researchers discover markers that identify breast cancer subtypes resistant to Herceptin

Using gene chips to profile tumors before treatment, researchers at Harvard and Yale Universities found markers that identified breast cancer subtypes resistant to Herceptin, the primary treatment for HER2-positive breast cancer. They say this advance could help further refine therapy for the 25 to 30 percent of breast cancer patients with this class of tumor.

20 Feb 2007

Endoplasmic reticulum (ER) News and Research

Physiological differences between men and women impact colorectal cancer progression

Benefits of Herceptin are lasting

New discoveries on genes implicated in Fanconi anaemia

Obese people more likely to have persistent or severe persistent asthma

Promoter hypermethylation is common in breast cancer

Specific genes identified that are most likely to become cancer promoters when exposed to DNA promoter hypermethylation

Influence of the cellular microenvironment on breast cancer

Succimer therapy improves balance and movement in lead-exposed children

Decrease in breast cancer incidence linked to drop in HRT

Breast cancer incidence continues to trend low in 2004

Drop in HRT use linked to decrease in breast cancer rates

New findings on salicylates may lead to more effective aspirin-like drugs

Although breast cancer mortality has declined as a whole, declines are greatest for women under 70

Chemotherapy and tamoxifen combination improves survival for early-stage breast cancer patients

Triple negative breast cancers more common among women who are African American and Hispanic, under 40 years old

New system to speed critical care to acute heart attack patients

Penwest confirms action on Oxymorphone patent application

New method for identifying viruses and bacteria that cause common infections in children

Tamoxifen offers long-term benefits for breast cancer prevention among women at high risk

Researchers discover markers that identify breast cancer subtypes resistant to Herceptin

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News